Exelixis, Inc. Q2 FY26 Results — Earnings Call Analysis
Published 30 May 2026 | Biotechnology | Market Cap: ₹12.9K Cr
- CABOMETYX revenue and demand continue strong growth; Q1 2026 U.S. - Exelixis reiterated full-year 2026 financial guidance (page 3), indicating confidence in stable or growing earnings. - Strong current growth with first quarter 2026 CABOMETYX U.S.
From Exelixis, Inc.'s Q2 FY26 earnings-call transcript · updated 30 May 2026.
Price
₹51.45
Market Cap
₹12.9K Cr
P/E Ratio
16.5
Revenue Rank
Margin Rank
How does Exelixis, Inc. rank in Biotechnology?
Compare Exelixis, Inc. against every Biotechnology company this quarter on revenue, margins and earnings-call signals.
📊 Revenue & Sales Performance
Rank 3- →CABOMETYX revenue and demand continue strong growth; Q1 2026 U.S. net product revenues grew 8% YoY to $555 million.
- →CABOMETYX TRx volume increased 14% in Q1 2026 vs Q1 2025, outpacing market growth (7%).
- →CABOMETYX gained 3 share points from 44% to 47% in the oral TKI market basket in Q1 2026.
- →Highest number of new patient starts ever for CABOMETYX in Q1 2026, indicating strong momentum.
- →Expansion of GI sales team to grow CABOMETYX's neuroendocrine tumor market share, especially in community settings.
- →Full launch preparation underway for ZANZA (zanzalintinib) in colorectal cancer later in 2026, representing a $1.5 billion market opportunity.
- →ZANZA development includes seven ongoing or upcoming pivotal trials, aiming to establish leadership in RCC and GI cancers.
- →Ongoing share repurchase program reflects confidence and aims to enhance shareholder value alongside R&D and BD investments.
📈 Profitability & Margins
Rank 3- →Exelixis reiterated full-year 2026 financial guidance (page 3), indicating confidence in stable or growing earnings.
- →Strong current growth with first quarter 2026 CABOMETYX U.S. net product revenues up 8% YoY to $555 million (page 1/3).
- →Non-GAAP net income for Q1 2026 was $232.8 million, or $0.87 per share diluted, showing profitability and momentum (page 3).
- →The company expects to complete a $750 million stock repurchase plan by May 2026 and has authorized a new $750 million repurchase plan through December 2027, enhancing EPS through share count reduction (page 3).
- →Expanding CABOMETYX market share and launch of ZANZA in colorectal cancer later in 2026 expected to drive future revenue and earnings growth (pages 1/3).
- →Continued R&D investments and broad clinical pipeline provide potential upside but may increase near-term expenses (pages 2/10).
🏗️ Capital Expenditure Plans
Yes- →Exelixis is allocating capital across three key areas: R&D investments, business development (BD) opportunities, and share repurchases.
- →The company maintains a financially strong position with significant cash flows, enabling balanced funding of these priorities.
- →They prioritize R&D spend continuously, funding projects that demonstrate potential, while BD activities are overseen by senior leadership for strategic opportunities.
- →Share repurchases are ongoing, with recent repurchases totaling approximately $430.8 million in Q1 2026 and a new $750 million stock repurchase plan authorized in May 2026, expiring December 2027.
- →Strategic investments focus on advancing their pipeline, especially the development and upcoming launch of zanzalitinib (ZANZA) in colorectal cancer and expansion in renal cell carcinoma and neuroendocrine tumors.
- →They also remain open to external innovation through targeted BD at appropriate valuations.
💰 Fundraising & Capital Structure
No information- →No specific mention of new fundraising through debt or equity in the provided transcript.
- →Company emphasizes strong financial position with significant cash flows.
- →Capital allocation focuses on R&D, business development (BD) opportunities, and share repurchases.
- →Access to capital is noted, but no concrete plans for raising new funds through debt or equity disclosed.
- →Ongoing share repurchase program includes an additional $750 million authorization by the board.
- →Priority remains on disciplined investment in high-value opportunities and maintaining financial strength.
📋 Order Book & Pipeline
No informationKey Metrics
Revenue
Margin
Capex
Fundraise
Order Book
Continue your research
Others in Biotechnology this season
- Arrowhead Pharmaceuticals, Inc. (Q2 FY26)
Arrowhead Pharmaceuticals, Inc. Q2 FY26 quarterly results analysis. REDEMPLO launch momentum continues strong with prescriptions accelerating nearly threefold o
- Madrigal Pharmaceuticals, Inc. (Q2 FY26)
Madrigal Pharmaceuticals, Inc. Q2 FY26 quarterly results analysis. The company expects steady patient additions and robust net sales growth through 2026, with Q
- Ionis Pharmaceuticals, Inc. (Q2 FY26)
Ionis Pharmaceuticals, Inc. Q2 FY26 quarterly results analysis. DAWNZERA sales expected at $110M-$120M in 2026, driven by switches from existing prophylactics a
- BridgeBio Pharma, Inc. (Q2 FY26)
BridgeBio Pharma, Inc. Q2 FY26 quarterly results analysis. Attruby franchise shows durable growth with a 24% increase in net sales from Q4 and 392% YoY growth i
Frequently Asked Questions
What were Exelixis, Inc. Q2 FY26 results?
- CABOMETYX revenue and demand continue strong growth; Q1 2026 U.S. - Exelixis reiterated full-year 2026 financial guidance (page 3), indicating confidence in stable or growing earnings. - Strong current growth with first quarter 2026 CABOMETYX U.S.
What is Exelixis, Inc. share price analysis?
Exelixis, Inc. currently shows a below-average growth signal. The stock trades at a P/E of 16.5 with a market cap of $12,932. Investors should review the full earnings analysis for detailed insights.
Is Exelixis, Inc. planning capital expenditure?
- Exelixis is allocating capital across three key areas: R&D investments, business development (BD) opportunities, and share repurchases.
Keep Exelixis, Inc. on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.